Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: A pharmacokinetic study

Hepatology Research

Volumn 44, Issue 6, 2014, Pages 685-688

  Ishii, Takamichi ^a   Hatano, Etsuro ^a   Taura, Kojiro ^a   Mizuno, Tomoyuki ^b   Kawai, Tomoki ^b   Fukudo, Masahide ^b   Katsura, Toshiya ^b   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hemodialysis; Hepatocellular carcinoma; Renal failure; Sorafenib

Indexed keywords

ANTIVIRUS AGENT; DRUG METABOLITE; EPIRUBICIN; INTERFERON; IODINATED POPPYSEED OIL; M 2; PIPERACILLIN PLUS TAZOBACTAM; SORAFENIB; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMERGENCY WARD; END STAGE RENAL DISEASE; FATIGUE; FOLLOW UP; HEMODIALYSIS; HEPATITIS C; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LUNG ABSCESS; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SEPTIC SHOCK; SHOCK; STAPHYLOCOCCUS INFECTION; STAPHYLOCOCCUS LUGDUNENSIS; TREATMENT DURATION;

EID: 84901915980     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12156     Document Type: Article

References (10)

1. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
2. Shinsako K, Mizuno T, Terada T etal. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. Int J Clin Oncol 2010; 15: 512-514.
3. Castagneto B, Stevani I, Giorcelli L etal. Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report. Med Oncol 2011; 28: 1384-1388.
4. Ferraris E, Di Cesare P, Lasagna A, Paglino C, Imarisio I, Porta C. Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis. Tumori 2009; 95: 542-544.
5. Hilger RA, Richly H, Grubert M etal. Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int J Clin Pharmacol Ther 2009; 47: 61-64.
6. Rey PM, Villavicencio H. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology 2008; 74 (3-4): 245-246.
7. Masini C, Sabbatini R, Porta C etal. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int 2012; 110: 692-698.
8. Kennoki T, Kondo T, Kimata N etal. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn J Clin Oncol 2011; 41: 647-655.
9. Miller AA, Murry DJ, Owzar K etal. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009; 27: 1800-1805.
10. Strumberg D, Richly H, Hilger RA etal. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972.